Julien Sage

Are you interested in following scientists in the Human Tumor Atlas Network (HTAN)? If so, this starter pack is for you! go.bsky.app/AXaDeng

It's that time of year again!

Advancing therapeutics in small-cell lung cancer - Nature Cancer Thomas and colleagues review the latest preclinical and clinical studies on small-cell lung cancer and outline future directions on therapeutic strategies highlighting a role for reverse translation i...

Another REVIEW now ONLINE at Nature Cancer

'Advancing therapeutics in small-cell lung cancer'

✒️By Anish Thomas, Chirayu Mohindroo & Giuseppe Giaccone

🔗 www.nature.com/articles/s43...

Upcoming deadline for the EACR Cancer Neuroscience Conference: June 30th!!

Don't miss it and submit your abstract today 👇

Attending the 3rd Cologne Conference on Lung Cancer #CCLC, incredible mix of basic cancer research and translational/clinical science - so much progress, and, still so much left to do!

Hallmarks of stem cell aging As organisms age, somatic stem cells progressively lose their ability to sustain tissue homeostasis and support regeneration. Although stem cells are …

Excited to share our review on Hallmark of Stem Cell Aging! With Tom Rando and Peggy Goodell @goodell-lab.bsky.social!!

www.sciencedirect.com/science/arti...

Atul Butte died yesterday.
The world lost a giant.
A big bear of a man.
With a huge smile.
With love for everyone.
With energy that could power a room.
I loved everything about Atul.
I loved how he was always happy.
I loved how excited he was about science and helping people.

I heard this morning that my informatics colleague Dr. Atul Butte passed after a battle with cancer. He was a giant in the field & inspired many of us over his distinguished career. He was a passionate champion of the power of big data & his impact on our field is immeasurable. RIP Atul & thanks.

The current and emerging immunotherapy paradigm in small-cell lung cancer - Nature Cancer Zhang and colleagues provide an overview of the current and emerging landscape of immunotherapy-based therapies for small-cell lung cancer.

🚨REVIEW ARTICLE JUST OUT at Nature Cancer!
'The current and emerging #immunotherapy paradigm in small-cell #lungcancer'

✏️By Lauren Byers, Jianjun Zhang and colleagues

🔗 www.nature.com/articles/s43...

Call for Group leaders in Innovative Biology Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

The Montpellier Institute of Molecular Genetics is recruiting group leaders (open rank). IGMM studies fundamental mechanisms underlying cellular processes and their links to human pathologies. Montpellier 🇨🇵 is an absolutely wonderful place to live. Deadline 31st October. jobrxiv.org/job/montpell...

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | NEJM Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Wheth...

A big advance for patients with SCLC today —

www.nejm.org/doi/full/10....

FOXA2 promotes metastatic competence in small cell lung cancer - Nature Communications Small cell lung cancer presents high and multi-site metastatic potential. Here, the authors discover that FOXA2, regulated by ASCL1, promotes multi-site metastasis in small cell lung cancer by inducin...

First Bluesky post…
New paper out, following on FOXA observations of the @juliensage.bsky.social lab; nice collaboration with the @joanmassague.bsky.social lab led by a shared post-doc, Kenta Kawasaki www.nature.com/articles/s41...

Our most recent Synthetic Biology for Sustainability symposium was a great success. Lots of excellent ideas and creative approaches to sustainability. And a wonderful group of scientists too! Check here for more info on our Syn Bio efforts (sb.stanford.edu)

Stanford faculty elected to National Academy of Sciences Seven Stanford researchers join the scholarly society, which works to promote science for public good.

Congratulations to Stanford Cancer Institute member @michellemonje.bsky.social, who is one of the 120 newly elected members of the National Academy of Sciences. news.stanford.edu/stories/2025... @nasonline.org

Cell cycle duration determines oncogenic transformation capacity - Nature Total cell cycle duration is a key hallmark of cancer initiation, and determines whether defects in apoptosis, senescence, immune surveillance, angiogenesis, DNA repair, polarity and proliferation lea...

new out in Nature www.nature.com/articles/s41...

The cell-division cycle is faster in cell types prone to forming cancer Some types of cell are more likely than others to give rise to tumours. A rapid cell cycle is a newly identified predictor of cancer susceptibility.

Some types of cell are more likely than others to give rise to tumours. A rapid cell cycle is a newly identified predictor of cancer susceptibility.

https://go.nature.com/42WjSd1

Our latest, in Science Advances: In vivo CRISPR screen revealed sgRNAs that switch chemosensitive SCLC PDXs to become resistant.We validated KEAP1 as key hit and found KEAP1 alterations in IMpower133 trial, where active NRF2 links to reduced survival in chemo arm www.science.org/doi/10.1126/... 1/2

Packed room at the #AACR25 Opening Ceremony, quite inspiring to be with thousands of cancer researchers !

Flyer for the 2025 Next Generation Faculty Symposium (including QR code in top right corner). This symposium highlights the work of exceptional early-career scientists in the broad field of quantitative biological and biomedical sciences, with a track record of excellence in research, leadership, mentorship, and community engagement. These early career scientists are preparing to launch a faculty search. Applications are due May 30th, 2025.

Hello Community!
Are you a postdoc/grad student preparing to launch a faculty search? Do you have a track record of excellence in research, leadership, mentorship & community engagement? Apply to the 2025 Next Generation Faculty Symposium: www.berkeleystanfordnextgensymposium.com! Pls repost! (1/3)

SCI members Max Deihn & Ash Alizadeh have developed a blood test for #CancerDetection and characterization that uses #CirculatingTumor RNA. www.nature.com/articles/s41...

Our latest work now online in Cell:

Rewriting regulatory DNA to dissect and reprogram gene expression

Our new method (Variant-EFFECTS) uses high-throughput prime editing + flow sorting + sequencing to precisely measure effects of noncoding variants on gene expression

Thread 👇

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment...

Great news for patients with SCLC, the results of the Phase 3 trial with the DLL3 BiTE Tarlatamab (IMDELLTRA) are positive! Hopefully we will see the data soon! www.prnewswire.com/news-release...

Challenges of small cell lung cancer heterogeneity and phenotypic plasticity - Nature Reviews Cancer In this Review, Simpson et al. summarize the emergent understanding of molecular subtypes of small cell lung cancer (SCLC). They discuss how intratumour heterogeneity and dynamic tumour plasticity may challenge the success of immune and molecular subtype-targeted therapies and argue that combination therapies, monitored by serial liquid biopsy-based biomarkers, will be needed to improve the outcomes of patients with SCLC.

🐰#Weekendrreading #Review🚨

Caroline Dive&Co discuss the challenges associated with #ITH and plasticity in #SCLC and argue that combination therapies&liquid biopsy-based biomarkers are needed to improve patient outcomes.
📖⬇️
@cruk-mi.bsky.social

I’m excited that this review co-written with my colleague and friend Carl Walkley is now published! We focused on genetic studies, from mouse to human, that uncover the functional importance and mechanisms of RNA editing enzyme ADAR1 and reveal exciting therapeutic potential. #ADAR #RNAediting

Congrats Debbie!

Lung Cancer Prevention Laboratory Pioneering research in lung cancer to improve diagnosis, treatment and prevention

I am excited to announce that my laboratory @ucl.ac.uk is now open!

We are hiring so please contact us if you are interested.

www.caswelllaboratory.com

Wrapping up #SCLC25 in NYC with a legend in the lung cancer field, Dr. John Minna! So much progress in the SCLC field in the past few years!!

As Trump Cuts Cancer Research Funding, Billionaire Sean Parker Wants To Scale It Up With a new key hire, the Napster cofounder’s cancer fighting non-profit is ready to back the science both governments and markets leave behind.

My latest: Sean Parker's cancer fighting non-profit announced that former American Cancer Society CEO Karen Knudsen will be helming the organization. Parker tells me he plans to "double down" as government and markets pull back on research funding.

www.forbes.com/sites/alexkn...

It is incredible to see so many passionate researchers at the Stanford Cancer Institute Retreat today!

A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-induced Cell Death Developing cancer therapies that induce robust death of the malignant cell is critical to prevent relapse. Highly effective strategies, such as immunotherapy, exemplify this observation. Here we provi...

Cool paper from Crabtree and Gray labs:

www.biorxiv.org/content/10.1...